Alx Oncology Holdings (ALXO) Income from Continuing Operations (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Income from Continuing Operations of 21620000.0 for Q1 2026, up 5.3% sequentially from 22831000.0 in Q4 2025, and up 29.68% YoY from 16672444.19 in Q1 2025.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Income from Continuing Operations for 8 years, with the latest figure at 21620000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 29.68% year-over-year to 21620000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 95719000.0 (up 27.86% YoY) and the FY2025 annual result came in at 497000.0, up 99.53% from the prior year.
- Income from Continuing Operations rose to 21620000.0 in Q1 2026 per ALXO's latest filing, from 22831000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 21620000.0 in Q1 2026 and troughed at 50989000.0 in Q3 2023.
- A 5-year average of 32858470.59 and a median of 30743000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations plunged 1555.03% in 2022, then surged 39.77% in 2024.
- Over 5 years, Income from Continuing Operations stood at 30643000.0 in 2022, then slumped by 49.01% to 45662000.0 in 2023, then jumped by 36.11% to 29174000.0 in 2024, then increased by 21.74% to 22831000.0 in 2025, then rose by 5.3% to 21620000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 21620000.0, 22831000.0, and 22138000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Alx Oncology Holdings | 274.67 Mn | 274.67 Mn | - | -16.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.81 Mn |
| Mar 31, 2026 | -19.57 Mn |
| Dec 31, 2025 | -22.83 Mn |
| Sep 30, 2025 | -22.14 Mn |
| Jun 30, 2025 | -25.95 Mn |
| Mar 31, 2025 | -32.38 Mn |
| Dec 31, 2024 | -29.16 Mn |
| Sep 30, 2024 | -30.71 Mn |
| Jun 30, 2024 | -42.06 Mn |
| Mar 31, 2024 | -38.42 Mn |
| Dec 31, 2023 | -45.44 Mn |
| Sep 30, 2023 | -50.99 Mn |
| Jun 30, 2023 | -37.37 Mn |
| Mar 31, 2023 | -31.83 Mn |
| Dec 31, 2022 | -30.64 Mn |
| Sep 30, 2022 | -35.31 Mn |
| Jun 30, 2022 | -34.44 Mn |
| Mar 31, 2022 | -25.36 Mn |
| Dec 31, 2021 | -28.46 Mn |
| Sep 30, 2021 | -24.57 Mn |